Sadik Kassim

Chief Technology Officer at Danaher Genomic Medicines

Speaker

Sadik Kassim, Ph.D. is a biotechnology executive and scientist specializing in cell andgene therapy, bioprocessing, and translational research. He currently serves as ChiefTechnology Officer of Genomic Medicines for Danaher's Life Sciences companies.Previously, he was CTO at Vor Bio, where he built the technical operations team and leddevelopment for a CRISPR-edited HSPC product, as well as the company’s preclinicalCAR-T efforts. Before that, he was Executive Director at Kite Pharma, leadingmanufacturing process development for autologous CAR-T and TCR-based therapies. AsCSO at Mustang Bio, he oversaw the company’s preclinical and manufacturing foundation.He also led early analytical development at Novartis’ Cell and Gene Therapies Unit.Sadik has contributed to the development of three commercial CAR-T therapies—Kymriah, Yescarta, and Tecartus—and, most recently, to K-abe, the world’s first patientspecific,custom gene-edited drug product, developed and administered in a recordsettingsix months.He completed postdoctoral training at the National Cancer Institute (with Dr. StevenRosenberg), the University of Pennsylvania Gene Therapy Program (with Dr. Jim Wilson),and Johnson & Johnson’s Immunology Discovery group. He holds a B.S. in Cell andMolecular Biology from Tulane University and a Ph.D. in Microbiology and Immunologyfrom Louisiana State University.